DK3119384T3 - Behandling af intrahepatiske kolestastiske sygdomme - Google Patents
Behandling af intrahepatiske kolestastiske sygdomme Download PDFInfo
- Publication number
- DK3119384T3 DK3119384T3 DK15714132.6T DK15714132T DK3119384T3 DK 3119384 T3 DK3119384 T3 DK 3119384T3 DK 15714132 T DK15714132 T DK 15714132T DK 3119384 T3 DK3119384 T3 DK 3119384T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- mbx
- disease
- intrahepatic
- use according
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Claims (11)
1. Forbindelse, som er (F?)-2-(4-((2-ethoxy-3-(4-(trifluormethyl)phenoxy)pro-pyl)thio)-2-methylphenoxy)eddikesyre eller et salt deraf til anvendelse ved behandling af en intrahepatisk kolestastisk sygdom.
2. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er (F?)-2-(4-((2-ethoxy-3-(4-(trifluormethyl)phenoxy)propyl)thio)-2-methylphenoxy)eddike-syre-L-lysin-dihydratsalt.
3. Forbindelse til anvendelse ifølge et af kravene 1 eller 2, hvor forbindelsen indgives oralt.
4. Forbindelse til anvendelse ifølge et af kravene 1 til 3, hvor den daglige dosis af forbindelsen er 20-200 mg, når dosen af forbindelsen er beregnet som (F?)-2-(4-((2-ethoxy-3-(4-(trifluormethyl)phenoxy)propyl)thio)-2-methylphenoxy)eddikesyre.
5. Forbindelse til anvendelse ifølge krav 4, hvor den daglige dosis er 50-100 mg.
6. Forbindelse til anvendelse ifølge et af kravene 1 til 5, hvor forbindelsen indgives én gang om dagen.
7. Forbindelse til anvendelse ifølge et af kravene 1 til 6, hvor den intrahepati-ske kolestastiske sygdom er primær biliær cirrhosis, primær skleroserende kolangitis, progressiv familiær intrahepatisk kolestase eller Alagilles syndrom.
8. Forbindelse til anvendelse ifølge krav 7, hvor den intrahepatiske kolestastiske sygdom er primær biliær cirrhosis.
9. Forbindelse til anvendelse ifølge krav 7, hvor den intrahepatiske kolestasti-ske sygdom er primær skleroserende kolangitis.
10. Forbindelse til anvendelse ifølge krav 7, hvor den intrahepatiske kolesta-stiske sygdom er progressiv familiær intrahepatisk kolestase.
11. Forbindelse til anvendelse ifølge krav 7, hvor den intrahepatiske kolesta-stiske sygdom er Alagilles syndrom.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461968037P | 2014-03-20 | 2014-03-20 | |
| PCT/US2015/021502 WO2015143178A1 (en) | 2014-03-20 | 2015-03-19 | Treatment of intrahepatic cholestatic diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3119384T3 true DK3119384T3 (da) | 2018-12-03 |
Family
ID=52808186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15714132.6T DK3119384T3 (da) | 2014-03-20 | 2015-03-19 | Behandling af intrahepatiske kolestastiske sygdomme |
Country Status (32)
| Country | Link |
|---|---|
| US (5) | US9486428B2 (da) |
| EP (1) | EP3119384B1 (da) |
| JP (1) | JP6568577B2 (da) |
| KR (1) | KR102000332B1 (da) |
| CN (1) | CN106102734B (da) |
| AU (1) | AU2015231232B2 (da) |
| BR (1) | BR112016020260A8 (da) |
| CA (1) | CA2941401C (da) |
| CL (1) | CL2016002338A1 (da) |
| CY (1) | CY1120927T1 (da) |
| DK (1) | DK3119384T3 (da) |
| EA (1) | EA032358B1 (da) |
| ES (1) | ES2701094T3 (da) |
| FI (1) | FIC20253004I1 (da) |
| FR (1) | FR25C1031I2 (da) |
| HR (1) | HRP20181914T1 (da) |
| HU (2) | HUE041733T2 (da) |
| IL (1) | IL247920B (da) |
| LT (2) | LT3119384T (da) |
| MX (1) | MX367478B (da) |
| NL (1) | NL301338I2 (da) |
| NO (1) | NO2025035I1 (da) |
| NZ (1) | NZ724057A (da) |
| PH (1) | PH12016501769B1 (da) |
| PL (1) | PL3119384T3 (da) |
| PT (1) | PT3119384T (da) |
| RS (1) | RS57970B1 (da) |
| SI (1) | SI3119384T1 (da) |
| SM (1) | SMT201800690T1 (da) |
| UA (1) | UA120756C2 (da) |
| WO (1) | WO2015143178A1 (da) |
| ZA (1) | ZA201606043B (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| US10272058B2 (en) * | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| BR112016023269A8 (pt) | 2014-04-11 | 2021-06-29 | Cymabay Therapeutics Inc | uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| SMT202200171T1 (it) * | 2017-09-26 | 2022-05-12 | Cymabay Therapeutics Inc | Trattamento del prurito colestatico con seladelpar |
| CA3118965A1 (en) * | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| CA3148602A1 (en) | 2019-08-02 | 2021-02-11 | Acelot, Inc. | Small molecule drugs and related methods for treatment of diseases related to tdp-43, alpha-synuclein, huntingtin's protein and tau protein oligomer formation |
| US20210145775A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of intestinal barrier dysfunction and associated diseases |
| US20210145774A1 (en) | 2019-11-14 | 2021-05-20 | Cymabay Therapeutics, Inc. | Treatment of alcoholic liver disease |
| FI4225291T3 (fi) | 2021-02-01 | 2024-06-03 | Cymabay Therapeutics Inc | Kolangiopatioiden hoito seladelpaarilla |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7101993B1 (en) | 1990-01-11 | 2006-09-05 | Isis Pharmaceuticals, Inc. | Oligonucleotides containing 2′-O-modified purines |
| US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
| US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| AU5359496A (en) | 1995-03-06 | 1996-09-23 | Isis Pharmaceuticals, Inc. | Improved process for the synthesis of 2'-o-substituted pyrimidines and oligomeric compounds therefrom |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| ATE267207T1 (de) | 1996-02-14 | 2004-06-15 | Isis Pharmaceuticals Inc | Kohlenhydratmodifizierte luckenhafte oligonukleotide |
| US5883109A (en) | 1996-07-24 | 1999-03-16 | Bristol-Myers Squibb Company | Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug |
| US6066653A (en) | 1997-01-17 | 2000-05-23 | Bristol-Myers Squibb Co. | Method of treating acid lipase deficiency diseases with an MTP inhibitor and cholesterol lowering drugs |
| US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
| US7511131B2 (en) | 2002-11-13 | 2009-03-31 | Genzyme Corporation | Antisense modulation of apolipoprotein B expression |
| US7981915B2 (en) * | 2003-04-30 | 2011-07-19 | Beth Israel Deaconess Medical Center | Methods for modulating PPAR biological activity for the treatment of diseases caused by mutations in the CFTR gene |
| EP1667964B1 (en) | 2003-09-19 | 2009-07-22 | Janssen Pharmaceutica N.V. | 4-((phenoxyalkyl)thio)-phenoxyacetic acids and analogs |
| US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| JO3006B1 (ar) * | 2005-09-14 | 2016-09-05 | Janssen Pharmaceutica Nv | املاح ليسين مبتكرة من مشتقات حامض 4-((فينوكسي الكيل)ثيو) فينوكسي الخليك |
| JP5694941B2 (ja) | 2008-10-17 | 2015-04-01 | シーマベイ セラピューティクス，インコーポレイティド | 小型高密度ｌｄｌ粒子を減少させる方法 |
| MA34097B1 (fr) | 2010-03-30 | 2013-03-05 | Novartis Ag | Utilisations d'inhibiteurs de dgat1 |
| JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
| HK1224186A1 (zh) | 2013-11-20 | 2017-08-18 | Cymabay Therapeutics, Inc. | 纯阖家族型高胆固醇血症的治疗 |
| US20160279085A1 (en) | 2013-11-20 | 2016-09-29 | Cymabay Therapeutics, Inc. | Treatment of Severe Hyperlipidemia |
| US10272058B2 (en) | 2014-03-20 | 2019-04-30 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| BR112016023269A8 (pt) | 2014-04-11 | 2021-06-29 | Cymabay Therapeutics Inc | uso de ácido (r)-2-(4-((2-etóxi-3-(4-(trifluormetil)fenóxi)propil)-tio)-2-metilfenóxi)-acético ou sal do mesmo na fabricação de um medicamento para tratar doença hepática gordurosa não alcoólica ou esteato-hepatite não alcoólica |
| EA201790091A1 (ru) | 2014-06-26 | 2017-07-31 | Саймабэй Терапьютикс, Инк. | Лечение тяжелой гипертриглицеридемии |
| US10512622B2 (en) | 2017-07-14 | 2019-12-24 | Cymabay Therapeutics, Inc. | Treatment of intrahepatic cholestatic diseases |
| SMT202200171T1 (it) | 2017-09-26 | 2022-05-12 | Cymabay Therapeutics Inc | Trattamento del prurito colestatico con seladelpar |
| CA3118965A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Treatment of obesity and its complications |
| WO2020102337A1 (en) | 2018-11-16 | 2020-05-22 | Cymabay Therapeutics, Inc. | Combination treatment of nafld and nash |
-
2015
- 2015-03-19 PT PT15714132T patent/PT3119384T/pt unknown
- 2015-03-19 WO PCT/US2015/021502 patent/WO2015143178A1/en not_active Ceased
- 2015-03-19 BR BR112016020260A patent/BR112016020260A8/pt not_active Application Discontinuation
- 2015-03-19 RS RS20181363A patent/RS57970B1/sr unknown
- 2015-03-19 EP EP15714132.6A patent/EP3119384B1/en active Active
- 2015-03-19 CA CA2941401A patent/CA2941401C/en active Active
- 2015-03-19 HR HRP20181914TT patent/HRP20181914T1/hr unknown
- 2015-03-19 PL PL15714132T patent/PL3119384T3/pl unknown
- 2015-03-19 NZ NZ724057A patent/NZ724057A/en unknown
- 2015-03-19 CN CN201580014506.0A patent/CN106102734B/zh active Active
- 2015-03-19 KR KR1020167025636A patent/KR102000332B1/ko active Active
- 2015-03-19 HU HUE15714132A patent/HUE041733T2/hu unknown
- 2015-03-19 DK DK15714132.6T patent/DK3119384T3/da active
- 2015-03-19 SM SM20180690T patent/SMT201800690T1/it unknown
- 2015-03-19 US US14/663,027 patent/US9486428B2/en active Active
- 2015-03-19 ES ES15714132T patent/ES2701094T3/es active Active
- 2015-03-19 UA UAA201609525A patent/UA120756C2/uk unknown
- 2015-03-19 JP JP2017501116A patent/JP6568577B2/ja active Active
- 2015-03-19 MX MX2016012203A patent/MX367478B/es active IP Right Grant
- 2015-03-19 LT LTEP15714132.6T patent/LT3119384T/lt unknown
- 2015-03-19 AU AU2015231232A patent/AU2015231232B2/en active Active
- 2015-03-19 SI SI201530455T patent/SI3119384T1/sl unknown
- 2015-03-19 EA EA201691887A patent/EA032358B1/ru active IP Right Revival
-
2016
- 2016-08-31 ZA ZA2016/06043A patent/ZA201606043B/en unknown
- 2016-09-08 PH PH12016501769A patent/PH12016501769B1/en unknown
- 2016-09-15 CL CL2016002338A patent/CL2016002338A1/es unknown
- 2016-09-19 IL IL247920A patent/IL247920B/en active IP Right Grant
- 2016-09-21 US US15/271,460 patent/US9808436B2/en active Active
-
2017
- 2017-09-29 US US15/720,849 patent/US10220011B2/en active Active
-
2018
- 2018-11-28 CY CY181101264T patent/CY1120927T1/el unknown
- 2018-12-17 US US16/222,325 patent/US10828273B2/en active Active
-
2020
- 2020-10-03 US US17/062,545 patent/US11406611B2/en active Active
-
2025
- 2025-07-31 LT LTPA2025529C patent/LTPA2025529I1/lt unknown
- 2025-07-31 FI FIC20253004C patent/FIC20253004I1/fi unknown
- 2025-08-01 NO NO2025035C patent/NO2025035I1/no unknown
- 2025-08-05 FR FR25C1031C patent/FR25C1031I2/fr active Active
- 2025-08-13 HU HUS2500033C patent/HUS2500033I1/hu unknown
- 2025-08-13 NL NL301338C patent/NL301338I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11406611B2 (en) | Treatment of intrahepatic cholestatic diseases | |
| US11596614B2 (en) | Treatment of intrahepatic cholestatic diseases | |
| US11224580B2 (en) | Treatment of intrahepatic cholestatic diseases | |
| HK1229212B (en) | Treatment of intrahepatic cholestatic diseases | |
| HK1229212A1 (en) | Treatment of intrahepatic cholestatic diseases | |
| HK1262698B (en) | Seladelpar for the treatment of primary biliary cholangitis | |
| HK1262698A1 (en) | Seladelpar for the treatment of primary biliary cholangitis |